argenx raises approximately $100 million gross proceeds with NASDAQ IPO
(Thomson Reuters ONE) -
Regulated information - inside information
Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Brussels: ARGX,
Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline
of differentiated antibody-based therapies for the treatment of severe
autoimmune diseases and cancer, announced today the pricing of its initial
public offering in the United States (the "Offering") with anticipated gross
proceeds totalling approximately $100 million from the sale of 5,865,000
American Depository Shares ("ADSs"), at a price to the public of $17.00 per ADS.
All of the ADSs are being offered by argenx and each of the ADSs offered
represents the right to receive one ordinary share.
argenx had earlier increased the Offering from 3.6 million ADSs to 5.0 million
ADSs and has finally further increased the Offering to approximately 5.9 million
ADSs.
argenx's ordinary shares are listed on the regulated market of Euronext
Brussels. The ADSs are expected to begin trading on the NASDAQ Global Select
Market on May 18, 2017 under the symbol "ARGX". The Offering is expected to
close on May 23, 2017, subject to customary closing conditions. argenx has
granted the underwriters a 30-day option to purchase up to an additional
879,750 ADSs, representing 15% of the ADSs sold in the Offering, to cover over
allotments, if any. This option can be exercised during the 30 day period
commencing May 17, 2017.
Cowen and Company and Piper Jaffray & Co. are acting as joint bookrunning
managers for the Offering, and JMP Securities and Wedbush PacGrow are acting as
co-managers. Kempen & Co is argenx's advisor in connection with the Offering.
This Offering is being made only by means of a prospectus. Copies of the final
prospectus for this Offering may be obtained, when available, from Cowen and
Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue,
Edgewood, NY 11717, Attn: Prospectus Department, by telephone at (631) 274-2806
or by fax at (631) 254-7140 or from Piper Jaffray & Co., Attn: Prospectus
Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55403, or by telephone at
(800) 747-3924, or by email at prospectus(at)pjc.com.
A registration statement relating to these securities was declared effective by
the U.S. Securities and Exchange Commission ("SEC") on May 17, 2017.
This press release is for information purposes only and does not constitute, and
should not be construed as, an offer to sell or the solicitation of an offer to
buy or subscribe to any securities, nor shall there be any sale of securities in
any jurisdiction in which such offer, solicitation or sale is not permitted or
to any person or entity to whom it is unlawful to make such offer, solicitation
or sale. Reference is also made to the restrictions set out in "Important
information" below. This press release is not for publication or distribution,
directly or indirectly, in or into any state or jurisdiction into which doing so
would be unlawful or where a prior registration or approval is required for such
purpose.
About argenx
argenx is a clinical-stage biotechnology company developing a deep pipeline of
differentiated antibody-based therapies for the treatment of severe autoimmune
diseases and cancer. We are focused on developing product candidates with the
potential to be either first-in-class against novel targets or best-in-class
against known, but complex, targets in order to treat diseases with a
significant unmet medical need. Our ability to execute on this focus is enabled
by our suite of differentiated technologies. Our SIMPLE Antibody(TM) Platform,
based on the powerful llama immune system, allows us to exploit novel and
complex targets, and our three antibody engineering technologies are designed to
enable us to expand the therapeutic index of our product candidates.
For further information, please contact:
Joke Comijn, Corporate Communications Manager
+32 (0)477 77 29 44
+32 (0)9 310 34 19
info(at)argenx.com
Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
beth(at)sternir.com
Forward-looking Statements
The contents of this announcement include statements that are, or may be deemed
to be, "forward-looking statements". These forward-looking statements can be
identified by the use of forward-looking terminology, including the terms
"believes", "estimates", "anticipates", "expects", "intends", "may", "will", or
"should", and include statements argenx makes concerning the intended results of
its strategy, the estimated gross proceeds from the Offering and the anticipated
closing of the Offering. By their nature, forward-looking statements involve
risks and uncertainties and readers are cautioned that any such forward-looking
statements are not guarantees of future performance. argenx's actual results may
differ materially from those predicted by the forward-looking statements. argenx
undertakes no obligation to publicly update or revise forward-looking
statements, except as may be required by law.
Important information
No public offering will be made and no one has taken any action that would, or
is intended to, permit a public offering in any country or jurisdiction, other
than the United States, where any such action is required, including in the
European Economic Area. In the European Economic Area, the transaction to which
this press release relates will only be available to, and will be engaged in
only with, qualified investors within the meaning of Directive 2003/71/EC
(together with any applicable implementing measures in the relevant member state
of the European Economic Area and as amended, including by Directive
2010/73/EU, to the extent implemented in the relevant member state).
In addition, in the United Kingdom, the transaction to which this press release
relates will only be available to, and will be engaged in only with, investment
professionals falling within Article 19(5) of the Financial Services and Markets
Act (Financial Promotion) Order 2005, as amended (the "Order"), persons falling
within Article 49(2) (a) to (d) of the Order, and other persons to whom this
announcement may lawfully be communicated (all such persons together being
referred to as "relevant persons"). The securities referred to herein are only
available to, and any invitation, offer or agreement to subscribe, purchase or
otherwise acquire such securities will be engaged in only with relevant persons.
Any person who is not a relevant person should not act or rely on this
communication or any of its contents.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: argenx N.V. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 18.05.2017 - 03:57 Uhr
Sprache: Deutsch
News-ID 543474
Anzahl Zeichen: 7884
contact information:
Town:
Breda
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 139 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"argenx raises approximately $100 million gross proceeds with NASDAQ IPO"
steht unter der journalistisch-redaktionellen Verantwortung von
argenx N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
